CS-208mixed
Akdital S.A. (Groupe Akdital), Moroccan private hospital and clinic operator listed on the Casablanca Stock Exchange since December 2022
Post-IPO national hospital expansion programme (2022-2025): a MAD 1.2bn IPO to fund eight new units in 2023, four in 2024 and more than 3,000 beds by end-2024, followed by targets of 45 establishments by end-2025 and a first move abroad
- Region
- Africa
- Country
- Morocco
- Industry
- Hospitals and Health Systems
- Functions
- Strategy, Corporate Development & Transformation Office, Operations & Service Delivery, Treasury & Working Capital, HR & Workforce, Finance & FP&A
- Topics
- Operations cannot meet demand efficiently; Critical skills are missing or becoming obsolete; Investment capital is not generating returns; Cash is trapped and liquidity is tightening; Competing transformation programs overwhelm resources
- Starting situation
- New initiative
- Period
- 2022
- Last verified
- 5 November 2026
Executive summary
Akdital, a Moroccan private hospital group that had grown from 5 clinics in 2020 to 17 at its listing, raised MAD 1.2bn in a December 2022 IPO to expand across the country [C02, C04]. It promised eight new hospital units in 2023, four in 2024 and more than 3,000 beds by the end of 2024 [C02].
Three years later the network had grown to 41 establishments and 4,505 beds in all 12 regions, revenue had risen from MAD 1,035m to MAD 4,413m, and the company had begun to buy and build abroad [C05, C13]. The bed target was beaten (3,706 at end-2024) and cumulative openings over 2023-2024 exceeded the plan [C06, C09].
Two dated targets were missed: five units opened in 2023 rather than eight, and the network reached 41 establishments at end-2025 against a target of 45 [C02, C06, C10, C13]. Net debt more than doubled in 2025 and margins eased as new units ramped up [C14]. The case shows how a mid-sized operator can use public equity to scale fast on a demand tailwind, and why the timing of openings, the people pipeline and leverage need the same discipline as the headline growth.
Outcome: mixed
Documented shortfalls or reversals sit alongside documented gains. For example: an initial failure later recovered, or a strategic goal met while a major adverse event in the same programme was recorded.
Basis of the outcome
The programme's stated aims at the IPO were national geographic expansion and diversification of care, with eight new hospital units in 2023, four in 2024 and bed capacity above 3,000 by the end of 2024 (S02, S04). Documented gains: beds reached 3,706 at end-2024 (S09); 5 units opened in 2023 and 12 in 2024, so 17 against the 12 planned for the two years (S06, S09); the network covered all 12 regions by end-2025, against an ambition of 11 by 2025 (S06, S13); and revenue rose from MAD 1,035m in 2022 to MAD 4,413m in 2025 with net profit rising each year (S05, S13). Documented shortfalls: the 2023 openings (5) fell short of the eight announced at the IPO (S02, S06), and the network of 41 establishments at end-2025 fell short of the target of 45 by end-2025 reported in April 2025 (S10, S13); the 2025 results reports read do not mention that target (S13, S14). On the unit of count: the IPO plan spoke of eight new 'hospital units' for 2023 and four 'establishments' for 2024 (S02), while the company's own count of 2023 openings treats each facility as one establishment, counting a hospital and an oncology centre in Fès separately (S06), as it did with the 15 facilities at the IPO and the two Salé facilities (S01, S02); the comparison of five openings with eight is therefore made on the same unit. Net debt rose from MAD 1,753m to MAD 4,268m during 2025 and the EBITDA margin eased as new units ramped up (S09, S14).
Key figures
| Phase | Figure | Value | When | Verification |
|---|---|---|---|---|
| Before | Establishments and beds at the IPO | 15 and 1,602 | Nov 2022 | company_reported |
| Before | Revenue | MAD 1,035m | 2022 | press_reported |
| During | IPO size | MAD 1.2bn | Dec 2022 | company_reported |
| During | Openings in 2023 against 8 announced | 5 | 2023 | company_reported |
| After | Beds against target of more than 3,000 | 3,706 | end-2024 | press_reported |
| After | Establishments against target of 45 | 41 | end-2025 | press_reported |
| After | Revenue | MAD 4,413m | 2025 | press_reported |
| After | Net debt | MAD 4,268m | end-2025 | press_reported |
- company_reported
- A company statement, press release or investor presentation that no one has independently checked.
- press_reported
- A journalist's own reporting.
Practices this case bears on
- SupportsMake a few quantified, dated commitments, publish them, and report against them, including the misses BP-004
- SupportsSecure the scarce delivery skills early, and build the pipeline in-house when the market cannot supply it BP-018
- SupportsAnnounce only targets the evidence supports, build synergy estimates from shared data, and re-base them openly BP-033
- SupportsSeparate the programme's own effect from tailwinds, shocks and one-off gains before claiming credit BP-035
- SupportsJudge growth and customer strategies by unit economics and customer behaviour, not by totals or activity BP-037
- SupportsFinance and size big bets so the company survives a downturn in the first years BP-040
- SupportsWrite exit and pause criteria at approval, and treat impairments as triggers to re-test the strategy BP-042
- SupportsSecure the cash runway before you need it, and measure liquidity at its worst point BP-044
- SupportsMeasure and report each business separately before deciding its future BP-051
- SupportsPlan on the downside: assume the legacy business declines faster and the cycle turns, and have the cost playbook ready BP-054
- SupportsTest whether your capabilities really transfer before betting on a new market or exporting a model BP-056
- SupportsGrow by a multiple only after the operating system has been proven at the new scale BP-072
Sources
- S01 Deuxième introduction en bourse de l'année: les détails de la prochaine IPO du groupe Akdital · not stated, Le360, 2022-11-22 · accessed 2026-11-05
- S02 Akdital en bourse: les détails de l'opération · not stated, Bourse News, 2022-11-22 · accessed 2026-11-05
- S03 Akdital obtient le feu vert de l'AMMC pour son introduction en bourse · not stated, La Vie éco, 2022-11-22 · accessed 2026-11-05
- S04 Mediterrania Capital Partners partially exits Akdital through an IPO · staff writer, Africa Global Funds, 2022-12-16 · accessed 2026-11-05
- S05 Akdital : Un chiffre d'affaires d'1 MMDH en 2022, et des perspectives d'investissement ambitieuses pour 2023 · Khadija Khettou, Hespress FR, 2023-04-04 · accessed 2026-11-05
- S06 Communiqué de presse: indicateurs du quatrième trimestre 2023 · Akdital, Akdital S.A., 2024-02-28 · accessed 2026-11-05
- S07 Akdital: 2023, une année de succès reflet d'une stratégie d'expansion ambitieuse · Majda Benthami, Le360, 2024-03-22 · accessed 2026-11-05
- S08 Communiqué de presse: indicateurs du troisième trimestre 2024 · Akdital, Akdital S.A., 2024-11-27 · accessed 2026-11-05
- S09 Akdital, une année de croissance exceptionnelle et d'engagements tenus · Hespress FR, Hespress FR, 2025-03-20 · accessed 2026-11-05
- S10 Groupe Akdital : des résultats solides en 2024 et des objectifs clairs pour l'avenir · Challenge, Challenge, 2025-04-05 · accessed 2026-11-05
- S11 Akdital: indicateurs annuels consolidés au 31 décembre 2024 · Akdital, Akdital S.A., 2025-03 · accessed 2026-11-05
- S12 Akdital: publication des comptes consolidés du premier semestre 2025 · Akdital, Akdital S.A., 2025-09 · accessed 2026-11-05
- S13 Akdital franchit le cap de 4 Mds de DH de chiffre d'affaires · Soubha es-siari, EcoActu, 2026-03-27 · accessed 2026-11-05
- S14 Akdital: résultats 2025 · not stated, Bourse News, 2026-03-26 · accessed 2026-11-05
- S15 AMO two years after generalization: what's the assessment? · La Vie éco, La Vie éco (English edition), 2025-02-21 · accessed 2026-11-05
- S16 Cliniques privées : Au Maroc, la santé est un business · Badr Kidiss, Allo Docteurs, 2024-08-07 · accessed 2026-11-05
Researched and fact-checked knowledgebase · Knowledgebase built 5 November 2026 · Last verified 5 November 2026
Practices, their evidence grades and case summaries are public. Full case studies are available in AXIOM to subscribers and AXIOM Discover participants.

